23andMe price target lowered to 47c from 85c at Citi

Citi analyst David Lebowitz lowered the firm’s price target on 23andMe to 47c from 85c and keeps a Neutral rating on the shares. Last week, 23andMe presented data on two in-house immunotherapies 23ME-001473 and 23ME-00610, at the American Association for Cancer Research, the analyst tells investors in a research note. Separately, the firm says the shares remain out of compliance with Nasdaq rules requiring the stock price to be over $1.00, threatening its listing on the exchange. It believes the full financial impact from ongoing class action claims related to the company’s data theft remains unclear.